Evidence map›Paper›PMID 40072824›Full record

Trial reportInternational journal of hematology2025

Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.

Tatsunori Goto, Hiroshi Okamura, Takashi Ikeda, Yasuo Mori, Souichi Shiratori, Shin-Ichiro Fujiwara, Noriko Doki, Ken-Ichi Matsuoka, Yuta Katayama, Yi-Bin Chen and 5 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03657160 (A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03657160 phase3completednot on this map

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

TypeinterventionalSponsorMillennium Pharmaceuticals, Inc.Ran2019 to 2022Enrolled343ConditionsHematopoietic Stem CellsArmsVedolizumab Placebo, Vedolizumab
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tatsunori GotoDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Hiroshi OkamuraDepartment of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Takashi IkedaDivision of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Shizuoka, Japan.
Yasuo MoriDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Souichi ShiratoriDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Shin-Ichiro FujiwaraDivision of Hematology, Jichi Medical University, Tochigi, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Yuta KatayamaDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Yi-Bin ChenHematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA, USA.
Yngvar FløisandCentre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0379, Oslo, Norway.
Guillermo RossiterTakeda Development Center Americas, Inc. (at the time of the study), Cambridge, MA, USA.
Johan JanssonTakeda Development Center Americas, Inc. (at the time of the study), Cambridge, MA, USA.
Ryou NakayaTakeda Pharmaceutical Company Limited, Tokyo, Japan.
Takanori TeshimaDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan. teshima@med.hokudai.ac.jp.ORCID http://orcid.org/0000-0002-0941-271X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the randomized, double-blind, phase 3 GRAPHITE study (NCT03657160), anti-α

Indexed as

Antibodies, Monoclonal, HumanizedGastrointestinal DiseasesGraft vs Host DiseaseHematopoietic Stem Cell TransplantationAcute DiseaseAdultAgedDouble-Blind MethodEast Asian PeopleFemaleHumansJapanMaleMiddle AgedAntibodies, Monoclonal, HumanizedvedolizumabAllo-HSCTGraft-versus-host diseaseLower GIRandomized controlled trialVedolizumab

Identifiers

PMID40072824
PMCPMC12202567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.